Navigation Links
Unibioscreen and Drais Pharmaceuticals Partner to Develop and Commercialize UNBS 5162 for Treatment of Cancer
Date:9/15/2008

BRIDGEWATER, N.J., and BRUSSELS, Belgium, Sept. 15 /PRNewswire/ -- Drais Pharmaceuticals, Inc. and Unibioscreen S.A. today announced that they have entered into a global agreement to develop and commercialize UNBS 5162, one of Unibioscreen's investigational drug and potential breakthrough treatments for cancer. UNBS 5162 was discovered by Unibioscreen and is currently in Phase I trials in the United States in cancer patients with advanced solid tumors or lymphoma.

"This is an important milestone for Drais as we focus on building a portfolio of novel therapeutics," said Dr. Donna L. Tempel, president and chief executive officer of Drais Pharmaceuticals. "Partnering with innovative companies like Unibioscreen is an important step towards implementing our strategy of in-licensing and developing novel therapeutic treatments that meet unmet medical needs."

Under the terms of the agreement, Unibioscreen will receive upfront, development and regulatory milestones payments up to $31 million, in addition to commercial milestone payments. The license grants exclusive rights to Drais to develop and commercialize UNBS 5162 worldwide.

Christiane Verhaegen, chief executive officer and chief financial officer of Unibioscreen commented: "Unibioscreen's deal with Drais is a key milestone for both the development of the drug candidate and for the company as it provides validation of Unibioscreen's promising pipeline of potential cancer treatments in addition to monetary benefits. We are confident that Drais' experienced team will maximize the progression of UNBS 5162 and believe this agreement will provide excellent value for both partners." Denis Biju-Duval, Head of ING Belgium Corporate Investments added: "The agreement illustrates the ability of Unibioscreen to successfully exploit its unique technology and know-how. Unibioscreen will continue to innovate in the oncology sector."

About UNBS 5162

UNBS 5162 is a novel anti-cancer naphthalimi
'/>"/>

SOURCE Drais Pharmaceuticals, Inc. and Unibioscreen S.A.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vanda Pharmaceuticals Provides Update on Iloperidone
2. Cerimon Pharmaceuticals Announces Positive Results from a Phase II Clinical Study of Its Diclofenac Sodium Patch for Acute Pain
3. Jazz Pharmaceuticals, Inc. Announces Final Patient Has Completed Phase III Clinical Trial of Sodium Oxybate to Treat Fibromyalgia
4. Addrenex Pharmaceuticals Announces Positive Phase III Clinical Results for Clonicel to Treat ADHD
5. Celator Pharmaceuticals Receives Orphan Drug Designation for Anticancer Agent CPX-351
6. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
7. Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials
8. Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD)
9. Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies
10. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
11. Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)...  CARsgen, a leader in the development of Chimeric ... variety of cancers, today announced the completion of a ... China -based healthcare private equity fund.   ... development of new therapeutics for liver, lung, stomach and ... Shanghai Renji Hospital, the company plans to initiate clinical ...
(Date:11/26/2014)... and NEW YORK and ... -- As the leading distributor of market intelligence, MarketResearch.com ... research report by IQ4I Research and Consultancy focusing on ... learn more about IQ4I Research visit: http://www.marketresearch.com/land/publisher.asp?vendorid=4023&progid=86891 ... Active Pharmaceutical Ingredients Global Market – Forecast to 2020 ...
(Date:11/26/2014)... FRANCISCO , Nov. 25, 2014  goBalto, Inc., ... has been recognized as a winner of Red Herring,s ... a Global Top 100 North America award in 2013, ... international technology landscape. Red Herring,s Top 100 ... identifying promising new companies and entrepreneurs. Red Herring editors ...
Breaking Medicine Technology:CARsgen Completes Series A Financing 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 3goBalto Selected as a 2014 Red Herring Top 100 Global Company 2goBalto Selected as a 2014 Red Herring Top 100 Global Company 3
... Medical ( http://www.realtimemedical.com ), a global leader in ... selected to feature its latest advancements in diagnostic ... at e-Health 2012, as part of the Innovation ... from May 27 to 30, 2012 at the ...
... 25, 2012  Marken announced today that it has opened ... manage customer service operations and offer local service to ... Marken currently operates in the country through its partners, ... of the country.  This new office has been created ...
Cached Medicine Technology:Real Time Medical to Feature Diagnostic Imaging Software @ Innovation Showcase at e-Health 2012 2Marken Opens Branch Office In Seoul, South Korea 2
(Date:11/27/2014)... Let the Black Friday sales begin at ... on top, filled with skincare goodies, will delight and please ... while quantities last - no coupon required. See ... available on Amazon at the same sales prices. Links to ... page for ease. , The company published a 2014 ...
(Date:11/27/2014)... Guerrero (PRWEB) November 27, 2014 ... time individuals allot to sleep has lessened, and ... and laptops, the quality of sleep has eroded. ... falls asleep on the job (Reference: http://www.webmd.com/sleep-disorders/features/sleep-deprivation-workplace ... worker’s productivity index by an incalculable amount, leading ...
(Date:11/27/2014)... HealthDay Reporter , WEDNESDAY, Nov. ... to acquire a second language, new research suggests. But anyone ... gain a brain boost, the small study finds. ... study co-author Ping Li, co-director of the Center for Brain, ... more interesting, Li said, that "the brain networks of the ...
(Date:11/27/2014)... The founders of VIM & VIGR, a company ... compression socks, are proud to announce the debut of their ... Pressure (TM) knitting technology that is designed to increase the ... to adding flair and style to a product that has ... eye of a writer at The New York Times ...
(Date:11/27/2014)... VogueQueen.com is making every effort to offer more affordable ... the premier online supplier of elegant special occasion dresses ... huge selection of sexy prom dresses today. In addition ... many beautiful styles in its product line. Click to ... , “VogueQueen.com hopes to provide a truly unique shopping ...
Breaking Medicine News(10 mins):Health News:Big Christmas Sales Begin Today at Sublime Beauty® for all Christmas Gift Selections and Skincare Sets 2Health News:Research Shows Surprising Number of US Workers Affected by Lack of Sleep 2Health News:Some People May Be Pre-Wired to Be Bilingual 2Health News:Some People May Be Pre-Wired to Be Bilingual 3Health News:VIM & VIGR Announces Launch of Men’s Line of Compression Socks 2Health News:A New Collection of Sexy Prom Dresses Has Been Released by the Reliable Online Supplier VogueQueen.com 2
... March 10 In observance of,National Problem Gambling ... Revenue today highlighted the availability of counseling,and treatment ... addiction., "Problem gambling impacts not only the ... Secretary Dr. Calvin Johnson. "The Commonwealth,of Pennsylvania is ...
... N.J., March 10 Medco Health,Solutions, Inc. (NYSE: ... in,March as follows:, On Monday, March 17, 2008, ... Health Group, Inc., Medco,s specialty pharmacy,subsidiary, is scheduled to ... The presentation at the Boston Marriott Copley,Place will begin ...
... programs do not provide coverage to international ... ... Corners, one of the,industry,s most experienced travel health insurance providers, alerts,parents ... travel abroad for spring break vacations. Most health insurance,programs do not ...
... for less radical procedures may not be getting them, study ... skills and preferences may dictate treatment choices for kidney cancer ... patient,s general health, a new study finds. , This ... procedures, such as a partial nephrectomy where only part of ...
... March 10 ZARS Pharma, Inc. announced,today ... Pharma S.A. the,exclusive promotion and distribution rights ... Canada for Pliaglis(TM) (lidocaine and tetracaine) Cream,7%/7%, ... safe local,anesthesia in patients undergoing potentially painful ...
... Over One ... Million, PHILADELPHIA, ... have a form of,lupus, the chronic (incurable) disease that can result in ... and other health effects, including organ failure and death.,Lupus mostly strikes women ...
Cached Medicine News:Health News:State Agencies Highlight Available Assistance During Problem Gambling Awareness Week 2Health News:Medco to Present at Cowen and Company and Lehman Brothers Health Care Conferences 2Health News:Seven Corners Alerts Spring Breakers that They Need Travel Insurance to Vacation Abroad 2Health News:Seven Corners Alerts Spring Breakers that They Need Travel Insurance to Vacation Abroad 3Health News:Surgeon's Preferences Dictate Choice of Kidney Cancer Surgery 2Health News:Surgeon's Preferences Dictate Choice of Kidney Cancer Surgery 3Health News:ZARS Pharma Announces Worldwide License Agreement With Galderma Pharma S.A. for Pliaglis(TM), a Topical Local Anesthetic 2Health News:ZARS Pharma Announces Worldwide License Agreement With Galderma Pharma S.A. for Pliaglis(TM), a Topical Local Anesthetic 3Health News:Lupus Foundation to Host Community Outreach Initiatives 2Health News:Lupus Foundation to Host Community Outreach Initiatives 3Health News:Lupus Foundation to Host Community Outreach Initiatives 4
Full automatic, ready-to-use strip washer....
The Wellwash 4 Mk 2 combines high performance and flexibility with reliability, simplicity and ease of use....
MultiWash Advantage is a versatile microplate washer engineered for reliability. It is designed for lab environments to help streamline their daily processes....
... an unmatched combination of speed, accuracy and ... assessing and monitoring a patient's A1C levels., ... simple fingerstick and delivers A1C results in ... a proven and time-tested having received full ...
Medicine Products: